Insulet Co. (NASDAQ:PODD)’s stock price hit a new 52-week high during trading on Friday . The company traded as high as $171.97 and last traded at $168.96, with a volume of 42471 shares traded. The stock had previously closed at $164.87.
A number of equities analysts recently commented on the stock. Stifel Nicolaus assumed coverage on shares of Insulet in a research report on Tuesday, October 22nd. They issued a “hold” rating and a $163.00 target price on the stock. Jefferies Financial Group lifted their target price on shares of Insulet from $105.00 to $140.00 and gave the stock a “buy” rating in a research report on Tuesday, August 6th. BTIG Research cut shares of Insulet from a “buy” rating to a “neutral” rating in a research report on Monday, October 14th. Leerink Swann reiterated an “outperform” rating and issued a $185.00 target price (up previously from $160.00) on shares of Insulet in a research report on Tuesday, September 24th. Finally, Canaccord Genuity cut shares of Insulet from a “buy” rating to a “hold” rating and boosted their price objective for the company from $135.00 to $145.00 in a research report on Friday, October 18th. Ten analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $151.71.
The business’s 50-day simple moving average is $154.39 and its 200-day simple moving average is $130.33. The stock has a market cap of $8.73 billion, a PE ratio of 3,391.20 and a beta of 0.96. The company has a quick ratio of 3.91, a current ratio of 4.72 and a debt-to-equity ratio of 2.43.
In other news, CEO Shacey Petrovic sold 689 shares of Insulet stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $145.69, for a total transaction of $100,380.41. Following the sale, the chief executive officer now owns 94,510 shares of the company’s stock, valued at approximately $13,769,161.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael P. Spears sold 4,153 shares of the business’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $146.12, for a total transaction of $606,836.36. Following the sale, the senior vice president now directly owns 22,626 shares in the company, valued at approximately $3,306,111.12. The disclosure for this sale can be found here. Insiders have sold a total of 5,491 shares of company stock worth $806,124 in the last ninety days. Insiders own 3.50% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Advisors Preferred LLC bought a new stake in Insulet during the second quarter worth about $38,000. Harvest Fund Management Co. Ltd bought a new stake in Insulet during the second quarter worth about $43,000. Mitsubishi UFJ Securities Holdings Co. Ltd. bought a new stake in Insulet during the second quarter worth about $97,000. Steward Partners Investment Advisory LLC bought a new stake in Insulet during the second quarter worth about $119,000. Finally, Cerebellum GP LLC bought a new stake in Insulet during the third quarter worth about $122,000.
Insulet Company Profile (NASDAQ:PODD)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.
See Also: Put Option
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.